Grifols | GRFS - Net Income

Stock Price
8.08
Daily Change
0.09 1.13%
Monthly
4.80%
Yearly
12.07%
Q2 Forecast
7.87

Grifols reported EUR114.37M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Arca Biopharma USD -29.58M 694K Dec/2025
aTyr Pharma USD 24.56M 50.3M Dec/2025
Bio Path USD -976K 3.62M Sep/2025
Brainstorm Cell Therapeutics USD -2.11M 797K Sep/2025
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Cara Therapeutics USD -5.53M 621K Sep/2025
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Immunic USD -24.37M 2.99M Sep/2024
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
TherapeuticsMD USD -1.09M 356K Jun/2024